5 :: KDA, Korean Diabetes Association ::
string(8) "resource"
Subject    :    [2019 Aug;43(4)] Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
Writer KDA
Date 2019-10-10 16:42:11 Hit 756
LINK URL https://e-dmj.org/search.php?where=aview&id=10.4093/dmj.2018.0092&code=2004DMJ&vmode=FULL (Click 14)
Diabetes Metab J. 2019 Aug;43(4):432-446. English.
Published online Jun 19, 2019.  https://doi.org/10.4093/dmj.2018.0092
Copyright © 2019 Korean Diabetes Association
   
Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
Yu Mi Kang,1,* Chang Hee Jung,1,* Seung-Hwan Lee,2 Sang-Wook Kim,3 Kee-Ho Song,4 Sin Gon Kim,5 Jae Hyeon Kim,6 Young Min Cho,7 Tae Sun Park,8 Bon Jeong Ku,9 Gwanpyo Koh,10 Dol Mi Kim,11 Byung-Wan Lee,12 and Joong-Yeol Park1
1Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
2Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
3Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.
4Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
5Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
6Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
7Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
8Division of Endocrinology and Metabolism, Department of Internal Medicine, Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Korea.
9Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
10Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea.
11Medical Department of Diabetes and Cardiovascular, Sanofi-Korea, Seoul, Korea.
12Division of Endocrinology and Metabolism, Department of Internal Medicine, Graduate School, Yonsei University College of Medicine, Seoul, Korea.

Corresponding author: Joong-Yeol Park. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. Email: jypark@amc.seoul.kr Corresponding author: Byung-Wan Lee. Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Email: bwanlee@yuhs.ac.kr

 

*Yu Mi Kang and Chang Hee Jung contributed equally to this study as first authors.
 
Received June 05, 2018; Accepted December 08, 2018.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 
Abstract

Background

We aimed to investigate the effectiveness and safety of adding basal insulin to initiating dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin and/or sulfonylurea (SU) in achieving the target glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM).

Methods

This was a single-arm, multicenter, 24-week, open-label, phase 4 study in patients with inadequately controlled (HbA1c ≥7.5%) T2DM despite the use of DPP-4 inhibitor and metformin. A total of 108 patients received insulin glargine while continuing oral antidiabetic drugs (OADs). The primary efficacy endpoint was the percentage of subjects achieving HbA1c ≤7.0%. Other glycemic profiles were also evaluated, and the safety endpoints were adverse events (AEs) and hypoglycemia.

Results

The median HbA1c at baseline (8.9%; range, 7.5% to 11.1%) decreased to 7.6% (5.5% to 11.7%) at 24 weeks. Overall, 31.7% subjects (n=33) achieved the target HbA1c level of ≤7.0%. The mean differences in body weight and fasting plasma glucose were 1.2±3.4 kg and 56.0±49.8 mg/dL, respectively. Hypoglycemia was reported in 36 subjects (33.3%, 112 episodes), all of which were fully recovered. There was no serious AE attributed to insulin glargine. Body weight change was significantly different between SU users and nonusers (1.5±2.5 kg vs. −0.9±6.0 kg, P=0.011).

Conclusion

The combination add-on therapy of insulin glargine, on metformin and DPP-4 inhibitors with or without SU was safe and efficient in reducing HbA1c levels and thus, is a preferable option in managing T2DM patients exhibiting dysglycemia despite the use of OADs.

   
Keywords:
Diabetes mellitus, type 2; Insulin glargine; Safety
 

Articles - Reviews in DMJ
No. Subject Date Hit ↑
Notice : [2019 Aug;43(4)] Glycosylated Hemoglobin in Subjects Affected by Iron-Deficiency Anemia [2019 Aug;43(4)] Glycosylated Hemoglobin in Subjects Affected by Iro... 2019-10-10 814
Notice : [2019 Aug;43(4)] Impact of Longitudinal Changes in Metabolic Syndrome Status over 2 Years on 10-Year Incident Diabetes Mellitus [2019 Aug;43(4)] Impact of Longitudinal Changes in Metabolic Syndrom... 2019-10-10 820
Notice : [2019 Aug;43(4)] Increased Serum Angiopoietin-Like 6 Ahead of Metabolic Syndrome in a Prospective Cohort Study [2019 Aug;43(4)] Increased Serum Angiopoietin-Like 6 Ahead of Metabo... 2019-10-10 802
Notice : [2019 Aug;43(4)] The Protective Effects of Increasing Serum Uric Acid Level on Development of Metabolic Syndrome [2019 Aug;43(4)] The Protective Effects of Increasing Serum Uric Aci... 2019-10-10 810
Notice : [2019 Aug;43(4)] Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus [2019 Aug;43(4)] Factors Related to Blood Intact Incretin Levels in ... 2019-10-10 800
Notice : [2019 Aug;43(4)] Diabetes Fact Sheets in Korea, 2018: An Appraisal of Current Status [2019 Aug;43(4)] Diabetes Fact Sheets in Korea, 2018: An Appraisal o... 2019-10-10 770
Notice : [2019 Aug;43(4)] Plasma Fetuin-A Levels and Risk of Type 2 Diabetes Mellitus in A Chinese Population: A Nested Case-Control Study [2019 Aug;43(4)] Plasma Fetuin-A Levels and Risk of Type 2 Diabetes ... 2019-10-10 757
Notice : [2019 Aug;43(4)] Lower Leg Fat Depots Are Associated with Albuminuria Independently of Obesity, Insulin Resistance, and Metabolic Syndrome (Korea National Health and Nutrition Examination Surveys 2008 to 2011) [2019 Aug;43(4)] Lower Leg Fat Depots Are Associated with Albuminuri... 2019-10-10 783
Notice : [2019 Aug;43(4)] Association between Serum Selenium Level and the Presence of Diabetes Mellitus: A Meta-Analysis of Observational Studies [2019 Aug;43(4)] Association between Serum Selenium Level and the Pr... 2019-10-10 763
Notice : [2019 Aug;43(4)] Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea [2019 Aug;43(4)] Effectiveness and Safety of Adding Basal Insulin Gl... 2019-10-10 756
Notice : [2019 Aug;43(4)] Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial [2019 Aug;43(4)] Additional Effect of Dietary Fiber in Patients with... 2019-10-10 771
Notice : [2019 Aug;43(4)] Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials [2019 Aug;43(4)] Asian Subpopulations May Exhibit Greater Cardiovasc... 2019-10-10 756
Notice : [2019 Aug;43(4)] 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea [2019 Aug;43(4)] 2019 Clinical Practice Guidelines for Type 2 Diabet... 2019-10-10 779
Notice : [2019 Aug;43(4)] Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications [2019 Aug;43(4)] Continuous Glucose Monitoring Sensors for Diabetes ... 2019-10-10 764
Notice : [2019 June;43(3)] Serum R-Spondin 1 Is a New Surrogate Marker for Obesity and Insulin Resistance [2019 June;43(3)] Serum R-Spondin 1 Is a New Surrogate Marker for Ob... 2019-06-28 2,122
Notice : [2019 June;43(3)] Association of Visit-to-Visit Variability of Blood Pressure with Cardiovascular Disease among Type 2 Diabetes Mellitus Patients: A Cohort Study [2019 June;43(3)] Association of Visit-to-Visit Variability of Blood... 2019-06-28 2,287
Notice : [2019 June;43(3)]  Oral Glucose Tolerance Testing Allows Better Prediction of Diabetes in Women with a History of Gestational Diabetes Mellitus [2019 June;43(3)] Oral Glucose Tolerance Testing Allows Better Pred... 2019-06-28 2,108
Notice : [2019 June;43(3)] Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study [2019 June;43(3)] Diabetes Mellitus and Cause-Specific Mortality: A ... 2019-06-28 2,144
Notice : [2019 June;43(3)]  Effectiveness of Exercise Intervention in Reducing Body Weight and Glycosylated Hemoglobin Levels in Patients with Type 2 Diabetes Mellitus in Korea: A Systematic Review and Meta-Analysis [2019 June;43(3)] Effectiveness of Exercise Intervention in Reducin... 2019-06-28 2,074
Notice : [2019 June;43(3)] Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study [2019 June;43(3)] Acarbose Add-on Therapy in Patients with Type 2 Di... 2019-06-28 2,518
Notice : [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in... 2019-06-28 2,052
Notice : [2019 June;43(3)] Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets [2019 June;43(3)] Understanding Bile Acid Signaling in Diabetes: Fro... 2019-06-28 2,050
Notice : [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Primary Cause of Adipose Tissue Inflammation [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Prima... 2019-06-18 2,299
292 [2017 Jun;41(3)] Satisfaction Survey on Information Technology-Based... 2017-07-06 9,725
291 [2017 Jun;41(3)] The Effect of 12 Weeks Aerobic, Resistance, and Com... 2017-07-06 9,569
290 [2017 Jun;41(3)] Impact of Gender on the Association between Low Ser... 2017-07-06 9,262
289 [2017 Jun;41(3)] Comparison of Antidiabetic Regimens in Patients wit... 2017-07-06 9,034
288 [2017 Jun;41(3)] Physician-Directed Diabetes Education without a Med... 2017-07-06 9,007
287 [2017 Apr;41(2)] Addition of Ipragliflozin to Metformin Treatment in... 2017-07-06 8,920
286 [2017 Apr;41(2)] Association between Blood Mercury Level and Viscera... 2017-07-06 8,913
285 [2017 Apr;41(2)] Diabetes Camp as Continuing Education for Diabetes ... 2017-07-06 8,885
284 [2017 Feb;41(1)] Relationship between Regional Body Fat Distribution... 2017-03-23 8,869
283 [2017 Apr;41(2)] Role of NO/VASP Signaling Pathway against Obesity-R... 2017-07-06 8,818

목록

Gets the previous 5 pages.   Go to previous page.  [1]   2   3   4   5     Go to next page. Gets the next  5 pages.